Aimmune Therapeutics (AIMT) Receives New Coverage from Analysts at Robert W. Baird

Robert W. Baird assumed coverage on shares of Aimmune Therapeutics (NASDAQ:AIMT) in a research note issued to investors on Wednesday morning. The brokerage issued an outperform rating and a $64.00 target price on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the company. Zacks Investment Research cut Aimmune Therapeutics from a buy rating to a hold rating in a report on Wednesday, December 6th. Credit Suisse Group boosted their price objective on Aimmune Therapeutics from $36.00 to $45.00 and gave the stock an outperform rating in a research note on Monday, October 23rd. Wedbush reissued an outperform rating and set a $70.00 price objective (up from $42.00) on shares of Aimmune Therapeutics in a research note on Monday, October 23rd. Cantor Fitzgerald assumed coverage on Aimmune Therapeutics in a research note on Tuesday, December 12th. They set an overweight rating and a $55.00 price objective on the stock. Finally, BidaskClub cut Aimmune Therapeutics from a buy rating to a hold rating in a research note on Saturday, December 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of Buy and an average target price of $55.43.

Shares of Aimmune Therapeutics (NASDAQ:AIMT) traded up $0.76 during mid-day trading on Wednesday, hitting $36.28. The stock had a trading volume of 233,300 shares, compared to its average volume of 359,215. Aimmune Therapeutics has a 1 year low of $15.97 and a 1 year high of $38.86.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.72) by $0.09. research analysts anticipate that Aimmune Therapeutics will post -2.52 EPS for the current fiscal year.

In other news, insider Douglas T. Sheehy sold 47,425 shares of the company’s stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $34.44, for a total transaction of $1,633,317.00. Following the transaction, the insider now owns 34,300 shares of the company’s stock, valued at $1,181,292. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Stephen George Dilly sold 1,154 shares of the company’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $26.24, for a total value of $30,280.96. The disclosure for this sale can be found here. Insiders have sold 274,986 shares of company stock worth $7,533,100 over the last three months. 24.56% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its stake in shares of Aimmune Therapeutics by 10.1% during the second quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 499 shares during the last quarter. Legal & General Group Plc grew its stake in shares of Aimmune Therapeutics by 26.6% during the second quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock valued at $160,000 after buying an additional 1,634 shares during the last quarter. Voya Investment Management LLC grew its stake in shares of Aimmune Therapeutics by 31.2% during the second quarter. Voya Investment Management LLC now owns 15,781 shares of the biotechnology company’s stock valued at $324,000 after buying an additional 3,757 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in shares of Aimmune Therapeutics during the second quarter valued at approximately $333,000. Finally, Citadel Advisors LLC bought a new position in shares of Aimmune Therapeutics during the second quarter valued at approximately $360,000. 73.34% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Aimmune Therapeutics (AIMT) Receives New Coverage from Analysts at Robert W. Baird” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/12/21/aimmune-therapeutics-aimt-receives-new-coverage-from-analysts-at-robert-w-baird.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit